All In Biotech

Drug Trial Radar · NCT06925061

Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

A Phase 2 Multicentre, Randomised, Parallel-arm, Placebo-controlled, Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Madeleine BezaultAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, multicenter study of the impact of oral administration of EXL01 in the prevention of post-operative endoscopic recurrence of Crohn's disease after surgery. Approximately 80 eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks or until a study or treatment discontinuation criterion is met. Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker). The primary objective is to compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo. Endoscopic recurrence will be assessed using the endoscopic score assessed by central reading at Week 24 after surgery. All participants will be followed for safety until 4 weeks after end of treatment.

Conditions

  • Crohn Disease (CD)

Interventions

  • After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeksDrug

    Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo.Time frame: From enrollment to the end of treatment at 24 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France · Recruiting

  • Hôpital Henri Mondor

    Créteil, France · Recruiting

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France · Recruiting

  • CHU Lille

    Lille, France · Recruiting

  • Hospices civils Lyon Sud

    Lyon, France · Recruiting

  • CHU Marseille Nord

    Marseille, France · Recruiting

  • CHU Montpellier

    Montpellier, France · Recruiting

  • CHU Nancy

    Nancy, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • CHU Nice Archet 2

    Nice, France · Recruiting

  • CHU Saint Louis

    Paris, France · Recruiting

  • Hôpital Saint Antoine

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.